A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: An eastern cooperative oncology group study

Cancer

Volumn 83, Issue 6, 1998, Pages 1102-1108

  Kalemkerian, Gregory P ^a,e   Jiroutek, Michael ^b   Ettinger, David S ^a   Dorighi, John A ^c   Johnson, David H ^d   Mabry, Mack ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Swedish American Hospital   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

All trans retinoic acid; Cisplatin; Combination chemotherapy; Etoposide; Experimental therapeutics; Lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; RETINOIC ACID;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TRETINOIN;

EID: 0032530604     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1102::AID-CNCR8>3.0.CO;2-9     Document Type: Article

References (38)

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Meet 1992;327:1434-41.
2. Doyle LA. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 1993;20:326-37.
3. Mabry M, Nelkin BD, Falco JP, Barr LF, Baylin SB. Transitions between lung cancer phenotypes - implications for tumor progression. Cancer Cells 1991;3:53-8.
4. Abeloff MD, Eggleston JC, Mendelsohn G, Ettinger DS, Baylin SB. Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. Am J Med 1979;66:757-64.
5. Johnson BE, Battey J, Linnoila I, Becker KL, Makuch RW, Snider RH, et al. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. J Clin Invest 1986;78:525-32.
6. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, et al. Myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 1991;51:1708-12.
7. Mabry M, Nakagawa T, Nelkin BD, McDowell E, Gesell M, Eggleston JC, et al. v-Ha-ras oncogene insertion: a model for tumor progression in human small cell lung cancer. Proc Natl Acad Sci USA 1988;85:6523-7.
8. Hoffmann C, Eichel G. Retinoids in development. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:387-441.
9. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-64.
10. Hong WK, Itri L. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. 2nd edition. New York: Raven Press, 1994:597-630.
11. Nervi C, Vollberg TM, George MD, Zelent A, Chambon P, Jetten AM. Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells. Exp Cell Res 1991;195:163-70.
12. Gebert JF, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG. High frequency of retinoic acid receptor β abnormalities in human lung cancer. Oncogene 1991;6:1859-68.
13. Kim YH, Dohi DF, Han GR, Zou CP, Oridate N, Walsh GL, et al. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Cancer Res 1995;55:5603-10.
14. Zhang XK, Liu Y, Lee MO, Pfahl M. A specific defect in the retinoic acid response associated with human lung cancer cell lines. Cancer Res 1994;54:5663-9.
15. Kalemkerian GP, Jasti RK, Celano P, Nelkin BD, Mabry M. All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer. Cell Growth Differ 1994;5:55-60.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive-stage small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
18. Gazdar AF, Carbone DP. The biology and molecular genetics of lung cancer. Austin: R.G. Landes, 1994.
19. Kalemkerian GP, Mabry M. Cellular and molecular biology of small cell lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. Boston: Blackwell Scientific, 1993:57-84.
20. Doyle LA, Giangiulo D, Hussain A, Park HJ, Yen RWC, Borges M. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 1989;49:6745-51.
21. Geradts J, Chen JY, Russell EK, Yankaskas JR, Nieves L, Minna JD. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993;4:799-809.
22. Takahashi T, Obata Y, Sekido Y, Hida T, Ueda R, Watanabe H, et al. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 1989;49:2638-8.
23. Rygaard K, Vindelov LL, Spang-Thomsen M. Expression of myc family oncoproteins in small-cell lung cancer cell lines and xenografts. Int J Cancer 1993;54:144-52.
24. Lee JS, Newman RA, Lippman SM, Huber MH, Minor T, Raber MN, et al. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 1993;11:959-66.
25. Pilot HC, Rubin J, Kovach JS, Adamson PC. All-trans-retinoic acid: a dose-seeking study in solid tumors. Ann NY Acad Sci 1993;691:250-2.
26. Warrell RP. Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996;47:555-65.
27. DeVore RF, Johnson DH. Chemotherapy of small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven, 1996:825-35.
28. Jing Y, Hashimoto S, Nakajo S, Nakaya K. Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells. Leuk Res 1994;18:299-304.
29. Guchelaar HJ, Timber-Bosscha H, Dam-Meiring A, Urges DA, Oosterhuis JW, deVries EGE, et al. Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoicacid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer 1993;55:442-7.
30. Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, et al. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996;2:511-20.
31. Formelli F, Cleris L. Synthetic retinoid fenretinide is cffective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993;53:5374-6.
32. Kalemkerian GP, Ramnath N. Retinoids and apoptosis in cancer therapy. Apoptosis 1996;1:11-24.
33. Cortes JE, Kantarjian H. O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994;73:2946-52.
34. Tallman MS. Differentiating therapy in acute myeloid leukemia. Leukemia 1996;10:1262-8.
35. Weber W, Obrecht JP. Entretinate, lomustine and bleomycin versus lomustine and bleomycin in advanced squamous cell lung carcinoma. Cancer Treat Rep 1983;67:847-8.
36. Naik H, Kalemkerian G, Pienta KJ. 4-Hydroxyphenylretinamide in the chemoprevention of cancer. Adv Pharmacol 1995;33:315-47.
37. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, Mabry M. Fenretinide inhibits growth and induces apoptosis in small cell lung cancer cell lines. J Natl Cancer Inst 1995;87:1674-80.
38. Kalemkerian GP, Slusher R, Ramalingam S, Mabry M. Fenretinide inhibits growth and potentiates etoposide cytotoxicity in small cell lung cancer. Proc Am Assoc Cancer Res 1995;36:510.